Latest / Investor Exchange / IHH Healthcare Posts Double-Digit Growth For Q3 2025

Transcript

IHH Healthcare Posts Double-Digit Growth For Q3 2025 · Investor Exchange

• 0:02
  Time for another Investor Exchange podcast. Here are your hosts, Matt and Sally.
• 0:08
  Welcome to the Deep Dive. We're here to take those dense corporate reports,
• 0:12
  cut through all the noise, and really pull out the insights that matter,
• 0:15
  what's actually going on under the hood.
• 0:17
  And today, we are jumping straight into the Q3 2025 financials for IH Healthcare.
• 0:24
  Now, this is one of the biggest private hospital operators in the world.
• 0:27
  And if you just glance at the headlines, the numbers are pretty dazzling.
• 0:31
  We're talking double digit growth right across the top line.
• 0:33
  It suggests a real health care giant just going from strength to strength.
• 0:37
  It does. And that top line growth is a fantastic hook.
• 0:41
  As we get into the details, you see that IHH is really fighting a war on two
• 0:45
  fronts here. Two fronts. Yeah.
• 0:47
  On one side, you've got these relentless external pressures.
• 0:49
  We're talking intense pushback from payers on cost, medical inflation that just will not quit.
• 0:56
  And of course, all that global currency volatility.
• 0:58
  But on the other side, they're pouring capital into this huge multi-year internal transformation.
• 1:03
  The idea is to future-proof the business. So this Q3 report,
• 1:07
  it's less about pure growth and more about this collision between that massive
• 1:11
  investment and the relentless cost pressure.
• 1:14
  OK, let's unpack that collision then. Our mission for this deep dive is to figure
• 1:18
  out why this powerful engine of revenue growth seems to be, well,
• 1:22
  hitting some serious profitability headwinds.
• 1:24
  Let's start with the big numbers, the really bold ones for Q3 2025.
• 1:29
  Comparing year over year.
• 1:30
  Revenue hit RM 6.6 billion. That's a jump of 16 percent. And EBITDA,
• 1:35
  which is, you know, that crucial measure of cash operating profitability,
• 1:38
  it also surged 16 percent, up to RM 1.5 billion.
• 1:42
  And operationally, things are busy. Inpatient admissions are up 5 percent.
• 1:46
  Lab tests up 6. I mean, everything on the surface just screams success.
• 1:50
  And if you stop there, it's a perfect success story.
• 1:53
  The company is clearly seeing sustained high demand for quality health care.
• 1:58
  But for those of you who follow IHH closely, you'll know the number that truly
• 2:03
  matters, the one that reflects the real health of the core business,
• 2:06
  is the profit figure that strips out all the noise.
• 2:09
  The one-off games, asset sales, all that stuff. Exactly.
• 2:12
  We're talking about PTMI excluding
• 2:15
  exceptional items, we just call core earnings or underlying profit.
• 2:19
  And this is where the story completely flips on its head. The reported profit,
• 2:22
  that was up 15%, which sounds great. But if we ignore those one-time items and
• 2:28
  just focus on the core earnings...
• 2:30
  That underlying profit, it actually decreased 13% year-over-year down to RM462
• 2:36
  million. Yeah, wait, hold on.
• 2:37
  They brought in 16% more revenue...
• 2:40
  And their key profit figure shrank by 13%. That is a massive, massive disconnect.
• 2:46
  What is eating that entire revenue gain? That is the central question of this
• 2:50
  whole deep dive. And this isn't just a quarterly fluke, you know.
• 2:53
  The year-to-date 2025 figures show the same tension. Revenue grew 8%, right?
• 2:58
  But the underlying profit is down 5%. The simple answer is that the cost of
• 3:04
  doing business inflation,
• 3:05
  wages, and the heavy investment for that transformation plan,
• 3:09
  it's all accelerating faster than their ability to raise prices or find new
• 3:13
  efficiencies, especially in their legacy markets.
• 3:16
  So inflation is clearly eating their profit. It is. So we need to understand
• 3:20
  which parts of the business are actually fighting back.
• 3:23
  Let's pivot to the engines of that growth. Okay. So the CEO mentioned three
• 3:27
  main dribbles for that top line revenue.
• 3:29
  First, sustained demand. Second, a favorable case mix. So they're treating more
• 3:33
  acute, higher-value patients.
• 3:35
  And third, crucial price adjustments to fight inflation.
• 3:39
  And you have to add in the recent acquisitions. Island Hospital,
• 3:41
  Mainder Healthcare Group are definitely contributing to that top line. Right.
• 3:44
  But the real operational success story for Q3, it really all hinges on the emerging
• 3:49
  markets, Malaysia and India. They are the strategic bright spots here.
• 3:54
  Malaysia's performance is, well, it's genuinely compelling.
• 3:57
  They delivered 18% revenue growth and an outstanding 24% EBITDA growth year over year.
• 4:02
  So what's the strategy there? How did they manage such a high margin jump?
• 4:06
  The strategy is extremely smart,
• 4:08
  mainly because it directly addresses that headache of payer pressure.
• 4:11
  They're actively pivoting away from the high fixed cost, high capital inpatient
• 4:16
  services and moving toward a less capital intensive, more efficient daycare
• 4:23
  focused model. So think about it like this.
• 4:25
  A daycare model needs less physical space, fewer beds, lower nurse-to-patient
• 4:29
  ratios, and allows for faster patient turnover.
• 4:32
  It dramatically cuts overhead and helps contain that margin squeeze.
• 4:36
  That's a really clever move. That makes perfect sense.
• 4:38
  Usually moving away from complex inpatient stays would lower your average revenue
• 4:41
  per patient. But if you gain that much in efficiency, the EBITDA margin just soars.
• 4:46
  And they boosted medical tourism too, right?
• 4:48
  Absolutely. The Island Hospital acquisition is clearly paying off there.
• 4:52
  It's boosting their medical tourism share, which almost always carries higher
• 4:56
  margins because those services aren't subject to local payer negotiations.
• 5:00
  That is a successful strategic shift in action. Okay, let's move to India.
• 5:04
  The Fortis integration was this massive, massive undertaking.
• 5:08
  Are we starting to see the returns on that yet? We are, yes.
• 5:11
  Solid progress. India's EBITDA was up 10%. And the key driver here is integration.
• 5:17
  By formalizing the relationship through a, what they call an operations and
• 5:22
  maintenance services agreement, they're creating much closer synergies between
• 5:26
  Fortis and Glen Evels India. So they can consolidate best practices, improve supply chains.
• 5:31
  Exactly. They can operate as a single coordinated platform for growth across
• 5:34
  India. And that leads directly to margin improvements.
• 5:37
  Now let's talk about the real outlier for the quarter.
• 5:40
  Turkey and Europe. This region reported 19% revenue growth and an astronomical 29% EBITDA growth.
• 5:47
  I mean, that seems completely detached from the rest of the business.
• 5:49
  It is explosive growth, but you have to look at it through the Turkey lens.
• 5:53
  Operationally, they are performing strongly.
• 5:56
  Inpatient admissions, they were up 10%, so that's genuine volume growth. Okay.
• 6:00
  And they were strategic. They successfully implemented some significant price
• 6:05
  adjustments to keep pace with the soaring local inflation.
• 6:09
  The reported financial success is heavily amplified by the extraordinary economic climate there.
• 6:14
  And that's where that complicated accounting standard, MFRS 129,
• 6:18
  comes in, the hyperinflationary accounting.
• 6:20
  Can you break that down for us without it sounding like a finance exam? I'll try.
• 6:25
  Think of it this way. When a currency is hyperinflating, the historical cost
• 6:29
  of your physical assets or your past earnings, it quickly becomes meaningless. Right. It's worthless.
• 6:34
  So MFRS 129 forces them to restate the value of non-monetary items like property,
• 6:39
  and equipment using the current hyperinflation rate.
• 6:41
  And for this quarter, that generated a non-cash net monetary gain of RM245 million on paper.
• 6:48
  So while the operations are solid, that stunning 29% figure is partially an accounting benefit.
• 6:54
  Exactly. A benefit derived from successfully navigating and reporting within
• 6:58
  a hyperinflationary environment.
• 7:01
  Okay, so if Malaysia and India were the growth engines, the mature markets must
• 7:06
  have faced some real turbulence. They did.
• 7:08
  And what's fascinating here is the pressure on Singapore, which has traditionally
• 7:12
  been IHH's most stable, highest margin market. Singapore is the real shocker here.
• 7:19
  Q3 revenue was down 4 percent and EBITDA decreased 6 percent year over year.
• 7:23
  And the operational slump was even sharper in patient admissions,
• 7:27
  down 10 percent in the quarter.
• 7:29
  That is a significant lag for a flagship region. And that drop was caused by
• 7:33
  a trifecta of pressures that perfectly illustrate the margin squeeze hitting the whole company.
• 7:38
  First, that relentless payer pressure we mentioned.
• 7:40
  In a mature market, the payers have more leverage. They're resisting fee increases. Okay, and second?
• 7:46
  Second, high medical cost inflation, particularly wage inflation for specialized
• 7:50
  staff like nurses and doctors, which is really difficult to pass on fully to patients or payers.
• 7:55
  But the third factor, the phased opening of Mount Elizabeth Orchard.
• 7:59
  That seems counterintuitive. It's a brand new asset. Shouldn't that be a net
• 8:03
  positive? Not right away.
• 8:05
  When you phase in a new facility, you often face double running costs.
• 8:09
  You're maintaining operations at the old site while ramping up staffing and
• 8:13
  fixed costs at the new one. And there's disruption. There's unavoidable disruption, yes.
• 8:18
  They likely had to temporarily divert complex procedures or patient volumes
• 8:22
  during the transition, and that's probably what caused that 10% dip in admissions.
• 8:26
  It's an investment cost that hits your P&L immediately, long before the facility stabilizes.
• 8:32
  So connecting this back to the big picture, that massive double-digit revenue
• 8:36
  growth we saw at the start is essentially being masked or maybe absorbed by
• 8:40
  these macro challenges, payer pressure, labor inflation, and these startup costs.
• 8:45
  That's it exactly. And let's not forget foreign exchange.
• 8:48
  The group's reporting currency is the Malaysian ringgit.
• 8:51
  In Q3 2025, the ringgit strengthened against key currencies like the Singapore
• 8:55
  dollar and the Turkish lira.
• 8:57
  So when you translate all those foreign operations net assets back into a stronger
• 9:01
  ringgit, it negatively impacts the translated value. It puts further sort of
• 9:06
  technical pressure on the overall reported figures. It really is a game of two halves.
• 9:11
  Strong operational moves, but relentless financial and translational pressures
• 9:17
  eroding those core earnings.
• 9:18
  So given all these headwinds, the leadership is still saying they're extremely
• 9:22
  confident in their growth path.
• 9:24
  They're accelerating their transformation plan, this huge program to future-proof the business.
• 9:29
  That tells me they see this profitability dip as a necessary temporary cost of investment.
• 9:35
  That is the key takeaway, I
• 9:37
  think. They believe the investments will eventually overcome the pressure.
• 9:40
  The outlook for Singapore is all about recovery. We expect contributions from
• 9:44
  Mount Elizabeth Orchard to stabilize fully by, let's see, the second quarter of 2026.
• 9:49
  And that would remove that significant drag from the startup costs. It would.
• 9:53
  And what are the strategic shifts they're making in Singapore specifically?
• 9:56
  They're pioneering the shift to ambulatory care services.
• 9:59
  So there's that focus again on less capital-intensive models.
• 10:03
  And critically, Singapore is leveraging tech. They're the first private group
• 10:07
  to be fully participating in the National Electronic Health Record, or NEHR.
• 10:12
  How significant is that NEHR participation in real terms?
• 10:16
  Does that translate into a cost-saving right away, or is it a long-term strategic
• 10:20
  play we won't see profits from for a few years? It's a bit of both.
• 10:23
  The immediate benefits come from, you know, seamless patient records,
• 10:27
  faster admin processes. But the real gain is the long-term clinical efficiency
• 10:31
  and regulatory goodwill.
• 10:33
  It positions them as the modern integrated private provider,
• 10:36
  which is crucial for staying competitive in a high-tech market like that.
• 10:39
  And in India, what about the completion of the Fortis acquisition?
• 10:42
  Was that more than just checking a regulatory box? Oh, it's huge.
• 10:47
  Completing the Fortis open offer resolves years of regulatory complexity and uncertainty.
• 10:51
  It finally gives management the flexibility they need to explore future growth
• 10:55
  and potentially implement more efficient capital structures,
• 10:59
  maybe streamline debt or expand more rapidly without that regulatory cloud hanging over them.
• 11:04
  And this overall transformation strategy, it sounds like it's much more than
• 11:08
  just optimizing a few facilities. It's comprehensive. It's ambitious.
• 11:12
  It's driven by seven focus areas looking far beyond just clinical excellence.
• 11:17
  They're focused on new, lower-cost care models, engaging proactively with payers
• 11:22
  on pricing, and crucially, massively accelerating the adoption of tech,
• 11:27
  data, and AI across the entire group. I see.
• 11:30
  The overarching goal isn't just to sustain revenue growth. It's to aggressively
• 11:34
  drive profitability and sustain a healthy return on equity, despite all those
• 11:38
  external pressures. And it seems like they're managing their cash wisely while
• 11:41
  they fund all this. They are.
• 11:43
  Prudent capital management is paramount right now. And while they are funding
• 11:47
  expansion, their cash flow from operating activities remains incredibly strong,
• 11:52
  RN 4.4 billion year to date.
• 11:55
  That gives them the financial firepower to fund this ambitious agenda without
• 11:59
  relying too heavily on external borrowing, which helps mitigate those interest
• 12:03
  rate pressures. So let's pull all of this together.
• 12:06
  Okay, so the Q3 report demonstrates resilient revenue and EBITDA growth.
• 12:10
  That growth is fueled primarily by smart strategic pivots like that shift to
• 12:13
  daycare in Malaysia and the successful integration in India.
• 12:17
  But this growth came at a significant cost. The underlying core earnings faced
• 12:22
  intense pressure from medical and wage inflation, currency issues,
• 12:25
  and all those startup costs from their strategic projects.
• 12:28
  Right. So IHH is essentially paying
• 12:30
  a premium right now to overhaul and future-proof its massive business.
• 12:35
  The good news is they've crossed two big milestones. The full integration of
• 12:38
  Fortis has done, and the Mount Elizabeth Orchard stabilization is on the horizon for Q2 2026.
• 12:44
  Those are two major headwinds that should soon become tailwinds.
• 12:47
  And that shift toward less capital-intensive models like daycare and ambulatory
• 12:52
  services, that feels like a strong and, frankly, necessary response to how the industry is changing.
• 12:57
  So the critical question for you as you look ahead is this.
• 13:00
  Will those strategic investments in future-proofing finally translate into a
• 13:04
  positive recovery for core earnings in 2026?
• 13:07
  Will the sacrifice of these Q3 2025 margins actually pay off in sustained long-term profitability?
• 13:14
  That is the one figure you need to watch next year.
• 13:17
  That's it for this deep dive into IHH Healthcare. We'll catch you next time.